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This commentary discusses the findings of Udy and colleagues about the augmented renal clearance in septic and traumatized patients \[[@B1]\]. Antibiotic therapy is a key element of the treatment of patients with severe sepsis and septic shock, and success of antibiotic therapy is determined by multiple factors. Susceptibility of the microorganism to the antibiotic is crucial, but reaching an adequate concentration of the drug is equally relevant.

In recent years several studies found that plasma concentrations of antibiotics - with beta-lactam antibiotics investigated most intensely - are highly variable in critically ill patients, with a considerable number of patients not reaching adequate concentrations. Several factors, such as increased volume of distribution, hypoalbuminemia and increased elimination from the circulation, have been found to be involved in this phenomenon. As most of these antibiotics are primarily cleared via the kidneys, renal elimination has been studied most extensively, and the state of increased elimination of drugs via the kidney has been coined \'augmented renal clearance\' (ARC), which is defined as a creatinine clearance of 130 ml/minute/1.73 m^2^or higher \[[@B2]\]. The incidence of ARC has mainly been studied in smaller studies, and depending on the cutoff used for its definition and on the studied population, the incidence varied from 30% to 85% \[[@B3]-[@B5]\].

In their article, Udy and colleagues confirm the high incidence of ARC in a trauma and sepsis population, and found that age, trauma as admission diagnosis and a Sequential Organ Failure Assessment (SOFA) score of 4 or less were independently associated with ARC. Although they provided us with new insights in the characteristics of patients at risk of ARC, they could not translate their results into easy to use clinical guidance.

Identifying patients who present with ARC is obviously a desirable goal, in order to appropriately treat patients with severe infections. However, evaluation of kidney function in the ICU is notoriously difficult, and conventional biomarkers such as serum creatinine or estimates of glomerular filtration rate, such as Cockcroft-Gault or Modification of Diet in Renal Disease (MDRD) formulas, are not reliable, which is also the case in patients with ARC \[[@B6]\]. At present, creatinine clearance can most conveniently be measured using 8 or 24 h calculated creatinine clearance. When these data are not available, the results of the current study can serve as a guide to screen for ARC.

In the study by Udy and colleagues, cardiac index correlated with creatinine clearance - albeit poorly - and was not retained in the multivariate analysis. Although the methodology for cardiac index measurement used could also have influenced this finding, it may also demonstrate that renal clearance is determined by multiple factors and the search for surrogate markers may be elusive.

Irrespective of the findings reported, several questions remain unanswered. The incidence of ARC in more diverse and other ICU populations has been incompletely explored. Also, the dynamics of ARC during ICU stay have not been studied. Better methods for the early recognition of patients with ARC are necessary - potentially novel biomarkers such as neutrophil gelatinase-associated lipocalin (nGAL; currently mainly investigated in the setting of acute kidney failure) are worth exploring. Finally, diagnostic accuracy of different methods to diagnose ARC, including measured creatinine clearance, needs urgently to be determined.

Other than focusing on factors associated with the determinants of changed pharmacokinetics of antibiotics, performing actual therapeutic drug monitoring (TDM) may be an alternative approach. This is currently standard for drugs that have a narrow therapeutic index such as aminoglycosides or glycopeptides, but for other - safer - drugs, TDM may offer a solution to monitor efficacy rather than toxicity. However, TDM of beta-lactams is rarely used in routine practice because the potential benefits of TDM have not yet been established, and because of long turn-around time and high costs.
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